Search research articles
Contact Us
Filters
Showing results (531-540 of 621) with videos related to
Page
of 63
Sort By:
Journal of Neuroradiology = Journal De Neuroradiologie
|
January 1, 1992
CT and MRI of suprasellar lesions
J L Dietemann, C Cromero, T Tajahmady, et al.
Journal Francais D'Ophtalmologie
|
April 4, 2001
[An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients]
J F Rouland, G Peigne, E Sellem, et al.
Nature Communications
|
November 23, 2016
Inhibition of glycine transporter-1 in the dorsal vagal complex improves metabolic homeostasis in diabetes and obesity
Jessica T Y Yue, Mona A Abraham, Paige V Bauer, et al.
Neurology
|
January 28, 2004
Multiparametric MRI in a patient with adult-onset leukoencephalopathy with vanishing white matter
A Gallo, M A Rocca, A Falini, et al.
Journal of the Neurological Sciences
|
January 27, 2016
Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report
P Preziosa, V Martinelli, L Moiola, et al.
Brain : a Journal of Neurology
|
June 16, 2001
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment
F Barkhof, J H van Waesberghe, M Filippi, et al.
Neurology
|
February 1, 1995
Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study
M Filippi, D W Paty, L Kappos, et al.
Nature Medicine
|
April 8, 2015
Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network
Clémence D Côté, Brittany A Rasmussen, Frank A Duca, et al.
Brain : a Journal of Neurology
|
November 3, 1998
A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials
M Filippi, M Rovaris, R Capra, et al.
Neurology
|
November 9, 2005
Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials
F Barkhof, U Held, J H Simon, et al.
Page
of 63
Search research articles
Search
Showing results (531-540 of 621) with videos related to
Sort By:
Page
of 63
Journal of Neuroradiology = Journal De Neuroradiologie
|
January 1, 1992
CT and MRI of suprasellar lesions
J L Dietemann, C Cromero, T Tajahmady, et al.
Journal Francais D'Ophtalmologie
|
April 4, 2001
[An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients]
J F Rouland, G Peigne, E Sellem, et al.
Nature Communications
|
November 23, 2016
Inhibition of glycine transporter-1 in the dorsal vagal complex improves metabolic homeostasis in diabetes and obesity
Jessica T Y Yue, Mona A Abraham, Paige V Bauer, et al.
Neurology
|
January 28, 2004
Multiparametric MRI in a patient with adult-onset leukoencephalopathy with vanishing white matter
A Gallo, M A Rocca, A Falini, et al.
Journal of the Neurological Sciences
|
January 27, 2016
Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report
P Preziosa, V Martinelli, L Moiola, et al.
Brain : a Journal of Neurology
|
June 16, 2001
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment
F Barkhof, J H van Waesberghe, M Filippi, et al.
Neurology
|
February 1, 1995
Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study
M Filippi, D W Paty, L Kappos, et al.
Nature Medicine
|
April 8, 2015
Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network
Clémence D Côté, Brittany A Rasmussen, Frank A Duca, et al.
Brain : a Journal of Neurology
|
November 3, 1998
A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials
M Filippi, M Rovaris, R Capra, et al.
Neurology
|
November 9, 2005
Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials
F Barkhof, U Held, J H Simon, et al.
Page
of 63